Exozymes (EXOZ) Competitors $15.15 +0.07 (+0.46%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock EXOZ vs. RLAY, UPB, ZVRA, URGN, ARVN, ALT, DNA, SIGA, SEPN, and PRTCShould you be buying Exozymes stock or one of its competitors? The main competitors of Exozymes include Relay Therapeutics (RLAY), Upstream Bio (UPB), Zevra Therapeutics (ZVRA), UroGen Pharma (URGN), Arvinas (ARVN), Altimmune (ALT), Ginkgo Bioworks (DNA), SIGA Technologies (SIGA), Septerna (SEPN), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Exozymes vs. Relay Therapeutics Upstream Bio Zevra Therapeutics UroGen Pharma Arvinas Altimmune Ginkgo Bioworks SIGA Technologies Septerna PureTech Health Exozymes (NASDAQ:EXOZ) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Do analysts recommend EXOZ or RLAY? Relay Therapeutics has a consensus target price of $17.67, indicating a potential upside of 508.15%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders & institutionals have more ownership in EXOZ or RLAY? 97.0% of Relay Therapeutics shares are held by institutional investors. 4.9% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to EXOZ or RLAY? In the previous week, Relay Therapeutics had 7 more articles in the media than Exozymes. MarketBeat recorded 8 mentions for Relay Therapeutics and 1 mentions for Exozymes. Relay Therapeutics' average media sentiment score of 1.21 beat Exozymes' score of 0.67 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exozymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, EXOZ or RLAY? Exozymes has higher earnings, but lower revenue than Relay Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/ARelay Therapeutics$7.68M64.86-$341.97M-$2.23-1.30 Does the MarketBeat Community favor EXOZ or RLAY? Relay Therapeutics received 63 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/ARelay TherapeuticsOutperform Votes6370.00% Underperform Votes2730.00% Is EXOZ or RLAY more profitable? Exozymes' return on equity of 0.00% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A Relay Therapeutics N/A -45.75%-40.75% SummaryRelay Therapeutics beats Exozymes on 9 of the 11 factors compared between the two stocks. Get Exozymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetricExozymesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.70M$2.94B$5.40B$8.49BDividend YieldN/A1.72%5.22%4.11%P/E RatioN/A30.9526.7119.93Price / SalesN/A410.01395.44119.84Price / CashN/A168.6838.2534.62Price / BookN/A3.316.854.59Net IncomeN/A-$72.17M$3.23B$248.19M7 Day Performance9.00%6.36%5.35%2.21%1 Month Performance48.04%9.80%13.31%16.23%1 Year PerformanceN/A-27.03%17.58%8.00% Exozymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZExozymesN/A$15.15+0.5%N/AN/A$126.78MN/A0.0029Gap UpRLAYRelay Therapeutics3.3492 of 5 stars$2.73-1.6%$17.67+548.3%-55.0%$467.19M$7.68M-1.04330Positive NewsGap DownUPBUpstream Bio2.2283 of 5 stars$8.50-0.8%$56.50+565.1%N/A$456.71M$2.30M0.0038Positive NewsZVRAZevra Therapeutics3.2695 of 5 stars$8.28+1.7%$22.29+169.2%+83.6%$454.66M$23.61M-4.2220News CoverageAnalyst RevisionURGNUroGen Pharma4.1043 of 5 stars$9.71-1.6%$32.86+238.5%-41.6%$447.47M$90.40M-3.08200Trending NewsGap DownTrading HaltedARVNArvinas3.6196 of 5 stars$6.09+0.2%$20.91+243.7%-80.0%$444.15M$426.90M-2.20420ALTAltimmune2.6577 of 5 stars$5.76+1.0%$20.20+251.0%-27.2%$442.37M$20,000.00-3.7150Analyst RevisionGap DownDNAGinkgo Bioworks1.0425 of 5 stars$7.54-3.7%$5.77-23.5%N/A$435.55M$237.42M-0.57640Positive NewsSIGASIGA Technologies1.3703 of 5 stars$5.99+1.0%N/A-17.9%$427.22M$120.33M4.9840Positive NewsSEPNSepterna2.0785 of 5 stars$9.63-5.2%$33.00+242.7%N/A$425.26M$1.08M0.00N/AEarnings ReportAnalyst RevisionGap DownPRTCPureTech Health1.5357 of 5 stars$17.37+3.9%$45.00+159.1%-39.3%$417.23M$4.32M0.00100Gap Up Related Companies and Tools Related Companies Relay Therapeutics Competitors Upstream Bio Competitors Zevra Therapeutics Competitors UroGen Pharma Competitors Arvinas Competitors Altimmune Competitors Ginkgo Bioworks Competitors SIGA Technologies Competitors Septerna Competitors PureTech Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exozymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exozymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXOZ Stock Free EXOZ Stock Alerts